MicroPort’s Endovastec Reports Revenue and Profit Growth Amid Equity Decline

MicroPort Scientific ( (HK:0853) ) has issued an update.

Shanghai MicroPort Endovascular MedTech (Endovastec), a subsidiary of MicroPort Scientific Corporation, reported a 1.6% increase in revenue and a 13.4% rise in profit for the year ending December 31, 2024. Despite these gains, the total equity attributable to equity owners saw a slight decrease of 1.4%. The financial results, prepared under PRC accounting standards, are unaudited and only reflect Endovastec’s operations, not the entire group, prompting caution among investors.

More about MicroPort Scientific

MicroPort Scientific Corporation is a company incorporated in the Cayman Islands, focusing on the medical technology industry. It is involved in the development and manufacturing of medical devices, with a particular emphasis on endovascular and cardiovascular products. The company is publicly traded on the Hong Kong Stock Exchange.

YTD Price Performance: 29.34%

Average Trading Volume: 47,230

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $1.96B

For detailed information about 0853 stock, go to TipRanks’ Stock Analysis page.